AUTHORS
Cinthya J Zepeda Mendoza, Muhammad Yousuf2, Rong He, MD3, David Viswanatha, MD4, Naseema Gangat, MBBS5, Animesh Pardanani, PhD, MBBS6, Ayalew Tefferi, MD7
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background: Approximately 10–15% of essential thrombocythemia (ET) and primary myelofibrosis (MF) lack detectable canonical JAK2, CALR, or MPL mutations and are designated “triple-negative.” Prior Sanger, whole-exome, and targeted next-generation sequencing studies have shown non-canonical genetic alterations involving these 3 drivers, as well as mutations in other genes. Because targeted myeloid panels interrogate predefined regions and do not fully capture structural, copy-number, and non-coding variation, we performed high-depth whole-genome sequencing (WGS) to molecularly characterize a cohort of triple-negative ET and MF cases.
Methods: An institutional review board-approved protocol allowed retrospective collection of patients with clinically defined triple-negative ET and MF, established by ICC criteria (Blood 2022; 140:1200) and absence of canonical JAK2, CALR, and MPL alterations on a targeted NGS panel sensitive to 2% variant allele fraction (VAF). WGS was performed on peripheral-blood or bone-marrow DNA; paired-end 150-bp libraries yielded an average sequencing depth of ~72X (Illumina, San Diego, CA). Somatic and germline variant calling was performed as previously described (Novogene, Sacramento, CA) and variant analysis prioritized according to relevance in myeloproliferative neoplasms (MPNs) biology.
Results: A total of 21 patients with triple-negative disease, normal karyotype, and negative/non-canonical driver mutations by NGSHM at diagnosis were analyzed (2002–2025), including 11 with ET (52%) and 10 with MF (48%; including one autoimmune MF). ET patients had median hemoglobin of 13.0 g/dL and platelet count of 812 × 10^9/L; none had disease progression during follow-up. MF patients had median hemoglobin of 10.8 g/dL and platelet count of 146 × 10^9/L; anemia <10 g/dL, thrombocytopenia <100 × 10^9/L, and transfusion dependence occurred in 4/10 (40%); 2/10 (20%) experienced disease progression with cytopenias, increased transfusion need and symptom burden. No patient in this MPN cohort developed leukemic transformation or died at last follow-up.
No universal recurrent genetic lesion was identified by WGS, but biologically relevant candidates were detected in one ET (MPL p.S204F, VAF 20.6%) and one MF (MPL p.Ala497_Leu500del VAF 40.6%) cases. Additional relevant myeloid mutations included SH2B3 (p.E395K VAF 50%) in one ET case and CBL (p.R294W, 31%) in one MF case. Pathogenic and likely pathogenic variants suspicious for germline origin included SBDS (p.K62*, VAF 40%) in a case of ET and HPS6 (p.R463*, 50.2%) in one MF case. Potential germline variants of uncertain significance (VUS) included THPO (p.L59P VAF 63%) and DDX41 (p.R479W, VAF 48%) in two ET cases. Low-burden variants (<10%) involved genes commonly associated with subclonal and age-related clonal hematopoieis and included PTPN11 (p.P33T, VAF 7.1%) and DNMT3A (p.F732C, VAF 9.8%) in two ET cases and SF3B1 (p.Glu697_Lys700delinsAspPro, 4.5%) in one MF case. Overall, two ET and one MF cases had no reportable single nucleotide or indel variants. The auto-immune MF case had no reportable pathogenic or likely pathogenic variants. No structural or copy-number variants could be identified as a pathogenic contributor to any ET or MF cases. Additional analyses of the Mayo Clinic’s Molecular Hematopathology Lab database revealed recurrent presence of non-canonical MPL variants in cases referred for MPN, cytosis, cytopenia, MDS, and AML, including p.S204P (n=21), p.S204F (n=9), p.T486A (n=3), and L498 indel (n=1).
Conclusions: In keeping with prior literature, high-depth WGS demonstrated that routinely defined triple-negative ET and MF comprise a heterogeneous molecular category rather than a single genomic entity. Our cohort further supports non-canonical MPL alterations, including the previously reported p.S204F in ET, as likely pathogenic drivers of triple negative ET and MF. A subset of cases may be explained by non-canonical JAK–STAT/RAS pathway or potential germline origin alterations, which will require further functional studies, whereas low-burden mutations may represent clonal hematopoietic, secondary or subclonal events rather than primary disease drivers. These findings support stratification of clinically triple-negative cases into non-canonical driver-positive MPN, possible hereditary, secondary clonal findings, and genomically unresolved cases which may be explained by auto-immune disease.
DISCLOSURES
Cinthya J Zepeda Mendoza: No relevant conflicts of interest to declare.